Biolase Inc BIOL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BIOL is a good fit for your portfolio.
News
-
BIOLASE to Report First Quarter 2024 Results on May 13, 2024
-
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?
-
Thinking about buying stock in Xpeng, Ocugen, Quantum Computing, CONSERVATIVE BROADCAST MEDIA JOURNALISM, or BIOLASE?
-
Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024
-
BIOLASE to Report Fourth Quarter and Full Year 2023 Results on March 21, 2024
-
Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry
-
Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'
-
BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering
Trading Information
- Previous Close Price
- $0.17
- Day Range
- $0.17–0.18
- 52-Week Range
- $0.13–32.09
- Bid/Ask
- $0.17 / $0.18
- Market Cap
- $5.86 Mil
- Volume/Avg
- 2,302 / 5.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.00
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biolase Inc is a United States-based provider of laser systems for the dental industry. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 157
- Website
- https://www.biolase.com
Valuation
|
Metric
|
BIOL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.00 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BIOL
|
|---|---|
Quick Ratio | 0.61 |
Current Ratio | 1.26 |
Interest Coverage | −7.73 |
Quick Ratio
BIOL
Profitability
|
Metric
|
BIOL
|
|---|---|
Return on Assets (Normalized) | −52.06% |
Return on Equity (Normalized) | −510.31% |
Return on Invested Capital (Normalized) | −84.87% |
Return on Assets
BIOL
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Mgxttbzy | Rpzkdw | $182.6 Bil | |
SYK
| Stryker Corp | Rwyvpdvc | Hkw | $126.5 Bil | |
MDT
| Medtronic PLC | Bqvyzlfd | Zmkwklq | $108.3 Bil | |
BSX
| Boston Scientific Corp | Qjdnjps | Wkgkc | $106.9 Bil | |
EW
| Edwards Lifesciences Corp | Gjrwfsxhk | Lddlbbx | $51.7 Bil | |
DXCM
| DexCom Inc | Cbtrpmpktj | Yrp | $50.5 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Slvxlqfdbr | Sfmcz | $24.9 Bil | |
PHG
| Koninklijke Philips NV ADR | Hwpdldlx | Ngfgpn | $24.2 Bil | |
ALGN
| Align Technology Inc | Mdzfprl | Ffbjp | $21.6 Bil | |
PODD
| Insulet Corp | Ckkpnxrwyy | Bvlcn | $12.3 Bil |